tiprankstipranks
Beauty Farm Medical & Health Industry, Inc. (HK:2373)
:2373
Hong Kong Market
Want to see HK:2373 full AI Analyst Report?

Beauty Farm Medical & Health Industry, Inc. (2373) AI Stock Analysis

1 Followers

Top Page

HK:2373

Beauty Farm Medical & Health Industry, Inc.

(2373)

Select Model
Select Model
Select Model
Neutral 65 (OpenAI - Gpt-5.6Sol)
Rating:65Neutral
Price Target:
HK$19.00
▼(-2.51% Downside)
Action:Downgraded
Date:08/29/26
The score is driven primarily by improving growth and profitability alongside generally solid cash generation, but is held back by the sharp increase in leverage and only mixed technicals (still below the 200-day moving average). Valuation and dividend yield are supportive.
Positive Factors
Revenue Growth
Revenue expanded strongly through 2025, including a sharp 2025 step-up. This indicates meaningful business growth and supports greater scale over the next several quarters. If sustained, stronger revenue can reinforce operating leverage and provide more resources for investment.
Negative Factors
Higher Leverage
Debt-to-equity increased sharply to 1.27 in 2025 from 0.70–0.77 in the prior two years. Higher leverage raises financial risk, reduces flexibility during weaker operating periods, and may constrain the company's ability to fund growth or absorb unexpected pressure.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Revenue expanded strongly through 2025, including a sharp 2025 step-up. This indicates meaningful business growth and supports greater scale over the next several quarters. If sustained, stronger revenue can reinforce operating leverage and provide more resources for investment.
Read all positive factors

Beauty Farm Medical & Health Industry, Inc. (2373) vs. iShares MSCI Hong Kong ETF (EWH)

Beauty Farm Medical & Health Industry, Inc. Business Overview & Revenue Model

Company Description
Beauty Farm Medical and Health Industry Inc., established in 1993 and based in Shanghai, People's Republic of China, delivers comprehensive beauty and health management services across China. Its diverse offerings encompass traditional beauty trea...

Beauty Farm Medical & Health Industry, Inc. Financial Statement Overview

Summary
Fundamentals are constructive: strong revenue growth through 2025 and improved profitability (net margin up to 10.6% in 2025). Offsetting factors are the sharp rise in leverage (debt-to-equity up to 1.27 in 2025) and some uncertainty in cash-flow coverage metrics despite positive operating/free cash flow.
Income Statement
78
Positive
Balance Sheet
56
Neutral
Cash Flow
62
Positive
BreakdownDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue3.00B2.57B2.15B1.64B1.78B
Gross Profit1.47B1.19B977.10M717.84M833.79M
EBITDA603.50M427.49M644.82M452.43M554.51M
Net Income317.56M228.46M215.66M103.11M193.47M
Balance Sheet
Total Assets5.05B4.28B3.30B2.50B2.48B
Cash, Cash Equivalents and Short-Term Investments2.57B1.83B1.57B910.63M1.08B
Total Debt1.29B730.59M563.12M525.50M515.46M
Total Liabilities3.98B3.30B2.47B2.29B2.21B
Stockholders Equity1.02B944.64M801.90M188.75M257.36M
Cash Flow
Free Cash Flow932.01M682.44M466.27M241.21M536.76M
Operating Cash Flow999.09M796.63M625.51M382.00M669.93M
Investing Cash Flow-396.42M-340.85M-711.18M53.63M-385.35M
Financing Cash Flow51.79M-223.36M133.74M-432.82M-271.06M

Beauty Farm Medical & Health Industry, Inc. Technical Analysis

Technical Analysis Sentiment
Negative
Last Price19.49
Price Trends
50DMA
17.96
Negative
100DMA
18.17
Negative
200DMA
21.00
Negative
Market Momentum
MACD
-0.06
Positive
RSI
43.48
Neutral
STOCH
11.33
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2373, the sentiment is Negative. The current price of 19.49 is above the 20-day moving average (MA) of 18.45, above the 50-day MA of 17.96, and below the 200-day MA of 21.00, indicating a bearish trend. The MACD of -0.06 indicates Positive momentum. The RSI at 43.48 is Neutral, neither overbought nor oversold. The STOCH value of 11.33 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2373.

Beauty Farm Medical & Health Industry, Inc. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
67
Neutral
HK$352.42M10.764.28%7.86%-2.78%-24.77%
65
Neutral
HK$4.38B10.9133.37%4.09%16.70%38.98%
62
Neutral
HK$6.54B31.442.50%0.39%1.59%-58.55%
56
Neutral
HK$1.22B85.710.48%1.02%-3.26%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
48
Neutral
HK$64.62M4.2612.17%36.68%
48
Neutral
HK$1.03B31.341.27%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HK:2373
Beauty Farm Medical & Health Industry, Inc.
17.61
-17.83
-50.31%
HK:2135
Raily Aesthetic Medicine International Holdings Limited
0.12
<0.01
2.65%
HK:3886
Town Health International Medical Group Ltd.
0.18
-0.08
-31.52%
HK:6078
Hygeia Healthcare Holdings Co., Ltd.
10.36
-3.87
-27.20%
HK:6639
Arrail Group Ltd.
1.83
-0.40
-17.98%
HK:0722
UMP Healthcare Holdings Limited
0.42
-0.03
-6.04%

Beauty Farm Medical & Health Industry, Inc. Corporate Events

Beauty Farm Medical & Health Industry Updates 2025 Final Dividend Payment
Aug 31, 2026
Beauty Farm Medical Health Industry Inc., a Hong Kong-listed provider of medical beauty and health services, caters to consumers seeking clinical and wellness treatments in the fast-expanding Asian aesthetic and healthcare market. The company lev...
Beauty Farm Posts Double-Digit Profit Growth on Surging Client Visits
Aug 27, 2026
Beauty Farm Medical and Health Industry Inc. reported strong interim results for the six months ended June 30, 2026, with client visits at direct stores rising 32.0% to about 1.21 million and revenue up 29.0% to RMB1.88 billion. Gross profit grew ...
Beauty Farm Sets Board Meeting and Earnings Call for 2026 Interim Results
Aug 13, 2026
Beauty Farm Medical and Health Industry Inc. has set August 27, 2026, as the date for a board meeting to review and approve its interim results for the six months ended June 30, 2026, and to consider whether to declare an interim dividend for shar...
Beauty Farm boosts Naturade footprint in Hangzhou with RMB10m acquisition
Aug 5, 2026
Beauty Farm Medical Health Industry Inc. has agreed to acquire 100% equity interests in Hangzhou Naturade Health Technology Company Limited and Hangzhou Xiaoshan Naturade Medical Beauty Clinic Co., Ltd. The transaction, valued at RMB10 million, w...
Beauty Farm flags strong H1 profit surge on dual growth strategy
Jul 19, 2026
Beauty Farm Medical and Health Industry Inc. expects a sharp improvement in first-half 2026 results, projecting revenue of at least RMB1.88 billion, up more than 28% year on year, and net profit of no less than RMB235 million, an increase of at le...
Beauty Farm Channels RMB475 Million of Idle Funds Into Citibank Wealth Products
Jul 14, 2026
Beauty Farm Medical and Health Industry Inc., through its wholly owned unit Beauty Farm Hong Kong, has deployed a significant portion of its idle funds into bank wealth management instruments as part of its treasury management strategy. The compan...
Beauty Farm Wins Strong Shareholder Backing at 2026 AGM
Jun 26, 2026
Beauty Farm Medical Health Industry Inc. reported that shareholders overwhelmingly approved all resolutions at its annual general meeting held in Hong Kong on 26 June 2026. The meeting confirmed the company&#8217;s audited financial statements fo...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 29, 2026